Innovations and Issues in Mantle Cell Lymphoma

Slides:

Advertisements

Similar presentations

MCL: Should all Eligible patients with MCL receive HDT-ASCT upfront?

Advertisements

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, :00 PM.

Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)

Neue Perspektiven in der Therapie Follikulärer Lymphome.

MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.

Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.

Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.

Ruan J et al. Proc ASH 2013;Abstract 247.

Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.

1 Do we really need to transplant young patients with Mantle Cell Lymphoma? Brad Kahl, MD University of Wisconsin.

ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

Presented By Michele Cavo at 2016 ASCO Annual Meeting

Chen R et al. Proc ASH 2015;Abstract 518.

Fujiwara H et al. Proc ASH 2015;Abstract 181.

Mantle Cell Lymphoma: Approach to Induction Therapy

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Hot Off the Press: Changes in the Landscape of Multiple Myeloma

Relapsed/Refractory Follicular Lymphoma Conundrums

Presented By James Rubenstein at 2016 ASCO Annual Meeting

Peripheral T-Cell Lymphoma in 2013

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Disclosures Geisler: Advisory boards and IDMC’s:

Advances in Lymphoma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

R-CHOP for Frontline Follicular Lymphoma

R-CHOP Stem Cell Transplantation for Follicular Lymphoma

Updates in Follicular Lymphoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Novel and Emerging Approaches to Treating CLL

Activity Goals. Activity Goals Case Presentation.

Jonathan W. Friedberg M.D., M.M.Sc.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Updates in Lymphoma From Recent Congresses

Jonathan W. Friedberg M.D., M.M.Sc.

Recent Advances in the Treatment of Lymphoma

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

CME-Certified 2012 Hematology Tumor Board Series: Practical Solutions to Current Clinical Challenges in B-Cell Lymphoma.

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Minimal Residual Disease in CLL

Mutational Testing to Select Novel Targeted Therapies in AML

Stephen Ansell, MD, PhD Mayo Clinic

Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.

Follicular lymphoma Every patient should be treated at diagnosis

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Non-Chemotherapy Combinations in CLL

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

The Role of Maintenance Therapy in Multiple Myeloma

Assessing New Paradigms in CLL: MRD Negativity

Proteasome Inhibitors and Patients

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

First-Line FCR: Effect of del(17p) on PFS and OS

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Oral Treatment Strategies in CLL

Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson

Tailoring Therapy in the Newly Diagnosed Patient With CLL

How to Select Therapy in Relapsed/Refractory CLL

Mats Jerkeman Department of Oncology Lund University Sweden

Changing Paradigms in Relapsed/Refractory Indolent NHL

Program. Applying the Data and Practical Recommendations for Tailoring Treatment Selections for AML.

Treatment Initiation and Selection in Newly Diagnosed CLL

Presentation transcript:

Innovations and Issues in Mantle Cell Lymphoma

Program Goals

MCL

MIPI

Less- vs More-Intensive Initial Treatments

Watch and Wait

MCL Treatment by Patient Type

StiL: BR vs R-CHOP

R-FC vs R-CHOP → Maintenance IFN-alpha or Rituximab

Novel Agents

R-CHOP vs VR-CAP

Nontransplant Options Based on Randomized Data

ASCT Studies

Approach Comparison by Patient Characteristics

ASCT vs IFN-alpha European MCL Network

Outcomes According to MIPI Risk: Pooled Analysis of European MCL Network Trials

Other Approaches to MCL

PINNACLE: Bortezomib in Relapsed/Refractory MCL (Single-Arm Phase 2 Trial)

MCL-001 (EMERGE): Lenalidomide in Relapsed/Refractory MCL (Single-Arm Phase 2 Trial)

Upfront Lenalidomide + Rituximab

E1411: Phase 2 Intergroup Trial of Initial MCL Therapy in Older Patients

Phase 2: Ibrutinib in Relapsed/Refractory MCL

TRIANGLE Study: European MCL Network

Venetoclax (ABT-199)—Phase 1

Conclusions